The cGMP Specific 3′,5′ Cyclic Phosphodiesterase pipeline drugs market research report outlays comprehensive information on the cGMP Specific 3′,5′ Cyclic Phosphodiesterase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the cGMP Specific 3′,5′ Cyclic Phosphodiesterase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Cardiovascular, Genito Urinary System, and Ophthalmology which include the indications Erectile Dysfunction, Alzheimer’s Disease, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Benign Prostatic Hyperplasia, Unspecified Genito Urinary Disorders, Glaucoma, and Ocular Hypertension. It also reviews key players involved in cGMP Specific 3′,5′ Cyclic Phosphodiesterase targeted therapeutics development with respective active and dormant or discontinued products.
The cGMP Specific 3′,5′ Cyclic Phosphodiesterase pipeline targets constitutes close to 51 molecules. Out of which, approximately 44 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 3, 6, 10, 9, 1, 6, and 2 respectively. Similarly, the universities portfolio in Phase III, Preclinical, and Discovery comprises 2, 3, and 1 molecule.
cGMP Specific 3′,5′ Cyclic Phosphodiesterase overview
Cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE5) is a enzyme involved in regulating the levels of cGMP, a key signaling molecule in various physiological processes. It belongs to the phosphodiesterase family, responsible for catalyzing the hydrolysis of cyclic nucleotides, including cGMP and cyclic adenosine monophosphate (cAMP).
For a complete picture of cGMP Specific 3′,5′ Cyclic Phosphodiesterase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
